NYSE:TEVA 1 November 2025 - 29 April 2026

Teva’s financial turnaround appears to be gaining steam, driven by both top-line growth and disciplined cost management. Quarterly revenue has now grown year-over-year for 11 straight quartersinvesting.com, marking a sustained rebound after a difficult past decade. In Q3 2025, revenue rose ~3% YoY to $4.48 Binvesting.com, while adjusted earnings jumped to $0.78 per sharereuters.com. Notably, this beat Wall Street estimates by ~$0.10 and marked Teva’s strongest earnings surprise of 2025reuters.com. The growth engines are Teva’s newer branded drugs: movement-disorder treatment Austedo, migraine injection Ajovy, and schizophrenia depot UZEDY. Together these “innovative medicines” climbed 33% YoY and contributed $830 M this quarterinvesting.com, helping offset flat-to-declining sales in older generic categories. “Our key innovative brands…delivered a 33% increase…underscoring their impact on both patient outcomes and our financial performance,” CEO Richard Francis notedtevapharm.comtevapharm.com. Importantly, Austedo’s momentum led management to raise Austedo’s 2025 revenue outlook to $2.05–$2.15 Binvesting.com. This bodes well for continued earnings expansion, since these specialty products carry higher margins than commodity generics. Meanwhile, Teva’s core generics business – still the world’s largest generic drug franchise – is stable to modestly growing in key markets. In the U.S., generic and biosimilar revenues grew ~7% YoY in Q3investing.com, aided by new launches and